Monoclonal antibody approved for the treatment of moderate-to-severe Crohn's disease

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 2008年 / 43卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：40 / +
页数：2
相关论文
共 50 条
  • [41] Infliximab: A novel chimeric monoclonal antibody for the treatment of Crohn's disease
    Mouser, JF
    Hyams, JS
    [J]. CLINICAL THERAPEUTICS, 1999, 21 (06) : 932 - 942
  • [42] Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial
    Colombel, Jean-Frederic
    Sandborn, William J.
    Rutgeerts, Paul
    Kamm, Michael A.
    Yu, Andrew P.
    Wu, Eric Q.
    Pollack, Paul F.
    Lomax, Kathleen G.
    Chao, Jingdong
    Mulani, Parvez M.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (05): : 1170 - 1179
  • [43] Review article: medical treatment of moderate to severe Crohn's disease
    Scribano, M
    Prantera, C
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 : 23 - 30
  • [44] Efalizumab, a Human Monoclonal Anti-CD11a Antibody, in the Treatment of Moderate to Severe Crohn’s Disease: An Open-Label Pilot Study
    Dustin G. James
    Da Hea Seo
    Jiajing Chen
    Caroline Vemulapalli
    Christian D. Stone
    [J]. Digestive Diseases and Sciences, 2011, 56 : 1806 - 1810
  • [45] Efalizumab, a Human Monoclonal Anti-CD11a Antibody, in the Treatment of Moderate to Severe Crohn's Disease: An Open-Label Pilot Study
    James, Dustin G.
    Seo, Da Hea
    Chen, Jiajing
    Vemulapalli, Caroline
    Stone, Christian D.
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (06) : 1806 - 1810
  • [46] Monoclonal antibody therapy for Crohn's disease
    Selby, W
    [J]. INTERNAL MEDICINE JOURNAL, 2001, 31 (02) : 73 - 74
  • [47] ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE
    Magro, Fernando
    De Hertogh, Gert
    Protic, Marijana
    Chan, Lai Shan
    Pollack, Paul
    Feagan, Brian
    Harpaz, Noam
    Pai, Rish
    Reinisch, Walter
    [J]. GUT, 2022, 71 : A41 - A41
  • [48] COST-EFFECTIVENESS ANALYSIS OF BIOSIMILARS BASED TREATMENT SEQUENCES FOR MODERATE-TO-SEVERE CROHN DISEASE IN SPAIN
    Fernandez Santos, J. M.
    Monte Boquet, E.
    Borras Blasco, J.
    Romero de la Cruz, E.
    Gonzalez Galan, R.
    Singh, M. K.
    Sharma, V
    Merino-Bohorquez, V
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S362 - S362
  • [49] Anti-TNF antibody approved for Crohn's disease
    不详
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 (20) : 2073 - 2073
  • [50] The Safety of Ustekinumab Treatment in Patients With Moderate-to-Severe Crohn's Disease and Latent Tuberculosis/HBV Infection: A Nationwide Retrospective Study
    Liu, Rongbei
    Cao, Qian
    Li, Zhilun
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S562 - S562
12345